Eccentric topic of the Week, Neuropharmacology
Question 22:
The correct answer is D, cabergoline
Cabergoline is less effective than octreotide but it is available in an oral preparation. Octreotide suspension must be injected intramuscularly.
A. Octreotide -> Somatostatin analogue -> More than 90% of patients show a reduction in growth hormone levels, only approximately 50-60% achieve levels of less than 2 ng/ml
B. Nimodipine -> Calcium channel blocker -> No role in treating acromegaly
C. Pegvisomant -> Growth hormone receptor blocker -> growth hormone levels cannot be measured in routine assays because the drug itself interferes with growth hormone assays but pituitary-derived growth hormone increases by a third, serum IGF-I levels are normalized in over 90% of patients
D. Cabergoline -> Dopamine agonist -> approximately 60% of patients will show a reduction in growth hormone levels, only about 10-15% achieve a mean level of less than 2 ng/ml.
http://www.colenpublishing.com/
No comments:
Post a Comment